Phase i study assessing the safety and tolerability of barasertib (azd1152) with low-dose cytosine arabinoside in elderly patients with AML

Hagop M. Kantarjian, Mikkael A. Sekeres, Vincent Ribrag, Philippe Rousselot, Guillermo Garcia-Manero, Elias J. Jabbour, Kate Owen, Paul K. Stockman, Stuart D. Oliver

Research output: Contribution to journal › Article › peer-review

46 Scopus citations

Fingerprint

Dive into the research topics of 'Phase i study assessing the safety and tolerability of barasertib (azd1152) with low-dose cytosine arabinoside in elderly patients with AML'. Together they form a unique fingerprint.

Medicine & Life Sciences